Novo Nordisk, a player in the pharmaceutical industry with an impressive 85% gross profit margin according to InvestingPro data, has broadened its Wegovy® savings offer, now extending a reduced cost of $499 per month to all eligible cash-paying patients for various doses of the obesity treatment, Wegovy® (semaglutide) injection. The pharmaceutical company, which has demonstrated robust revenue growth of 25% over the last twelve months, announced today that the offer, which was previously exclusive to the NovoCare® Pharmacy, would now be available at retail pharmacies.
The updated savings program aims to make Wegovy® more accessible to individuals managing obesity, offering a 28-day supply at a lower price than the previous $650 per month. Patients with commercial insurance that does not cover obesity medicines can also benefit from this offer, while those with coverage may pay as little as $0, subject to a maximum savings of $225. This strategic pricing move comes as Novo Nordisk maintains its strong market position, with InvestingPro analysis showing an impressive return on assets of 25.89% and an overall financial health rating of GREAT.
https://in.investing.com/news/company-news/novo-nordisk-expands-wegovy-savings-program-93CH-4737414
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.